C. Mitea

Ogliari, F. R., Jongbloed, M., Vaes, R. D. W., Houben, R. M. A., Bartolomeo, V., van den Borne, B. E. E. M., Degens, J., Huijs, J. W. J., Pitz, C., Steens, M., Youssef-El Soud, M., Sollini, M., De Ruysscher, D. K. M., Mitea, C., & Hendriks, L. E. L. (2026). Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 1836-1846. https://doi.org/10.1007/s00259-025-07557-9

Lenaerts, M., de Mooij, C. M., Houwers, J. B., Mitea, C., Panosetti, M., de Boer, M., Keymeulen, K. B. M. I., Mottaghy, F. M., Lobbes, M. B. I., Nelemans, P. J., Smidt, M. L., & van Nijnatten, T. J. A. (2025). Prognostic value of molecular and radiologic characteristics on dedicated breast [<SUP>18</SUP>F]FDG PET/MRI in breast cancer patients treated with neoadjuvant chemo(targeted) therapy: a retrospective cohort study. EJNMMI Research, 16(1), Article 6. https://doi.org/10.1186/s13550-025-01338-z

Beekman, M. J., Terra, L., Stuursma, A., Heemskerk-Gerritsen, B. A. M., van Lennep, J. E. R., van Beurden, M., van Doorn, L. C., de Hullu, J. A., van Dorst, E. B. L., Mom, C. H., Slangen, B. F. M., Mitea, C., Slart, R. H. J. A., Snoeren, M. M., Stokkel, M. P., Verberne, H. J., de Keizer, B., Korse, C. M., Gaarenstroom, K. N., ... Zillikens, M. C. (2025). Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on bone mineral density. Osteoporosis International, 36(11), 2307-2317. https://doi.org/10.1007/s00198-025-07679-8

Gavriilidis, P., Mottaghy, F. M., Koole, M., van de Weijer, T., Mitea, C., van der Pol, J. A. J., van Nijnatten, T. J. A., Jansen, F. P., & Wierts, R. (2025). Impact of tissue-independent positron range correction on [<SUP>68</SUP>Ga]Ga-DOTATOC and [<SUP>68</SUP>Ga]Ga-PSMA PET image reconstructions: a patient data study. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2538-2548. Article 015014. https://doi.org/10.1007/s00259-024-07061-6

Boellaard, R., Zwezerijnen, G. J. C., Buvat, I., Champion, L., Hovhannisyan-Baghdasarian, N., Orlhac, F., Arens, A. I. J., Lobeek, D., Celik, F., Mitea, C., Huijbregts, J. E., Tolboom, N., de Keizer, B., Valkema, R., van Velden, F. H. P., Dibbets-Schneider, P., Wiegers, S. E., Lugtenburg, P. J., Barrington, S. F., & Zijlstra, J. M. (2025). Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check. Journal of Nuclear Medicine, 66(5), 802-805. https://doi.org/10.2967/jnumed.124.269271

Dall'Olio, F. G., Zrafi, W., Roelants, V., Ambrosini, V., Fourquet, A., Mitea, C., Passiglia, F., Bauckneht, M., Bonardel, G., Conci, N., Benitez, J. C., Arena, V., Namour, C., Naigeon, M., Monnet, I., Beshiri, K., Hoton, D., Dursun, S., Danlos, F. X., ... Et al. (2025). Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates. Clinical Cancer Research, 31(2), 352-364. https://doi.org/10.1158/1078-0432.CCR-24-1993

van Nijnatten, T. J. A., de Mooij, C. M., Mitea, C., Houwers, J., de Boer, M., Smidt, M. L., Mottaghy, F. M., & Wildberger, J. E. (2024). [18F]FDG whole-body PET-MR including an integrated breast MR protocol for locoregional and distant staging in breast cancer patients-a feasibility study. Insights into Imaging, 15(1), Article 243. https://doi.org/10.1186/s13244-024-01830-5

van der Broeck, L. C. A., Mitea, C., Loeffen, D., Poeze, M., Qiu, S., Geurts, J., & Blokhuis, T. J. (2024). Assessing diagnostic accuracy: ¹⁸F-FDG PET-CT scans in low-grade infection detection among post-traumatic long bone non-unions; a literature review and clinical data. Injury-International Journal of the Care of the Injured, 55(6), Article 111712. https://doi.org/10.1016/j.injury.2024.111712

van Amstel, F. J. G., de Mooij, C. M., Simons, J. M., Mitea, C., van Diest, P. J., Nelemans, P. J., van der Pol, C. C., Luiten, E. J. T., Koppert, L. B., Smidt, M. L., van Nijnatten, T. J. A., & REFINE Study Group (2024). Disease extent according to baseline [<SUP>18</SUP>F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer. British Journal of Surgery, 111(9), Article znae203. https://doi.org/10.1093/bjs/znae203

van de Weijer, T., Bemer, F., de Vos-Geelen, J., Hermans, B., Mitea, C., van der Pol, J. A. J., Lodewick, T., Wildberger, J. E., & Mottaghy, F. M. (2024). Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment. European Journal of Nuclear Medicine and Molecular Imaging, 51(8), 2420-2427. https://doi.org/10.1007/s00259-024-06659-0